Background: Breast cancer (BC) is the commonest type of female cancer worldwide and a leading cause of cancer-related deaths. Perlecan expression increases in aggressive breast cancers, pointing to a possible significance of this novel target therapy. Consequently, the current research investigates the immunohistochemical expression of Perlecan by tumor cells in female breast cancer and the correlation of such expression with the pathologic parameters of the tumors. Methods: A retrospective cross-sectional investigation was carried out. Seventy-four formalin-fixed, paraffin-embedded breast carcinoma tissue samples from patients undergoing modified radical mastectomy (MRM) or conservative breast surgery (CBS) were collected from the pathology department at Kasr El Aini Hospital. The paraffin blocks were sectioned and immunostained with Perlecan, and their expression was investigated in tumor cells and evaluated according to the H-score and classified into low and high expression. The expression was statistically correlated with the clinicopathological parameters of the cases. Results: Perlecan expression was low in 41 cases (55.4%) and high in 33 cases (44.6%). It showed a statistically insignificant correlation with all studied parameters, but increased Perlecan expression was directly associated with poor tumor prognostic factors including higher tumor grade, advanced T stage, N3 stage, advanced anatomic stage, high Ki-67 index, positive lymphovascular invasion and perineural invasion, luminal B molecular subtype, and HER2 over-expression. Conclusion: Perlecan expression measured by immunohistochemical staining is associated with aggressive characteristics in breast cancer, suggesting that Perlecan may help in cancer progression and can be investigated as a possible target therapy.
Amer Ismail, S., Helmy, E., Abdel Aziz, A., & Shibel, P. (2023). Immunohistochemical Evaluation of Perlecan (Heparan Sulphate Proteoglycan 2) Expression in Invasive Female Breast Carcinoma. Asian Pacific Journal of Cancer Prevention, 24(12), 4277-4283. doi: 10.31557/APJCP.2023.24.12.4277
MLA
Samar Ibrahim Amer Ismail; Engy Talaat Helmy; Ahmed Mahmoud Abdel Aziz; Passant Essam Eldin Shibel. "Immunohistochemical Evaluation of Perlecan (Heparan Sulphate Proteoglycan 2) Expression in Invasive Female Breast Carcinoma". Asian Pacific Journal of Cancer Prevention, 24, 12, 2023, 4277-4283. doi: 10.31557/APJCP.2023.24.12.4277
HARVARD
Amer Ismail, S., Helmy, E., Abdel Aziz, A., Shibel, P. (2023). 'Immunohistochemical Evaluation of Perlecan (Heparan Sulphate Proteoglycan 2) Expression in Invasive Female Breast Carcinoma', Asian Pacific Journal of Cancer Prevention, 24(12), pp. 4277-4283. doi: 10.31557/APJCP.2023.24.12.4277
VANCOUVER
Amer Ismail, S., Helmy, E., Abdel Aziz, A., Shibel, P. Immunohistochemical Evaluation of Perlecan (Heparan Sulphate Proteoglycan 2) Expression in Invasive Female Breast Carcinoma. Asian Pacific Journal of Cancer Prevention, 2023; 24(12): 4277-4283. doi: 10.31557/APJCP.2023.24.12.4277
)